Navigation Links
FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
Date:9/14/2007

First treatment approved to reduce invasive breast cancer risk in

postmenopausal women with osteoporosis

INDIANAPOLIS, Sept. 14 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved its osteoporosis drug EVISTA(R) (raloxifene HCl) for a new use to reduce the risk of invasive breast cancer in two populations: postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer.

"The FDA's decision marks a major milestone. For the first time, postmenopausal women with osteoporosis will have one treatment option that can help address two leading health concerns -- osteoporosis and invasive breast cancer," said Gwen Krivi, Ph.D., vice president of Lilly Research Laboratories. "Further, postmenopausal women at high risk for invasive breast cancer will have an alternative therapy for invasive breast cancer risk reduction."

EVISTA, a selective estrogen receptor modulator or SERM (recently classified by the FDA as an estrogen agonist/antagonist), is already approved for the prevention and treatment of osteoporosis in postmenopausal women. In July, the Oncologic Drugs Advisory Committee (ODAC) to the FDA voted to recommend approval for the new uses. Today's decision and the positive recommendation from ODAC were based on data submitted in November 2006 in a new drug application (NDA), evaluating clinical results from approximately 37,000 postmenopausal women that spanned nearly 10 years.

Earlier this year, the osteoporosis label for EVISTA was updated to include safety information from the Raloxifene Use for The Heart (RUTH) trial, which evaluated postmenopausal w
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA approves MyocondaR IND for MAP in Crohns Disease
2. FDA approves IND on Lead Product M6G
3. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
4. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
5. Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
11. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... BERKELEY, Calif. and ... CMC Biologics, Inc. , a global leader in ... therapeutic proteins, announced today that, as part of its ... expansion of its North American manufacturing facility in ... a single-use Bioreactor 6Pack™ facility.  The Bioreactor 6Pack™ configuration ...
(Date:6/30/2015)... ATLANTA , June 30, 2015 Legal-Bay ... the first bellwether trial in the multidistrict litigation (MDL) ... scheduled to begin October 13 th , 2015. There ... Inc. which have been consolidated before a federal judge ... that the first bellwether trial will begin in October ...
(Date:6/29/2015)... BANGALORE , June 30, 2015 ... segmented by Primary Packaging Material (Plastic, Glass, Paper, Metal) ... IV Bags, Mini-jars, Pouches, Syringes, Tubes, Vials, Sachets) - By ... Europe , Asia Pacific , ... and Africa ) - discussing Industry ...
Breaking Medicine Technology:CMC Biologics Expands GMP Manufacturing Capacity in the United States 2CMC Biologics Expands GMP Manufacturing Capacity in the United States 3Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 2Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 3
... Technologies, Inc. was honored with the Belfast Ambassador Award ... Stormont, Belfast. The award was presented to the company by ... developing areas of Belfast, Ireland. HeartSine CEO ... in Stormont on behalf of HeartSine, said, "We are honored ...
... revised Concepts in Clinical Pharmacokinetics , a web-based ... Georgia. Developed in cooperation with the American Society of ... Continuing Education and College of Pharmacy, the new Online ... fundamental principles of absorption, distribution, metabolism, and the elimination ...
Cached Medicine Technology:HeartSine Technologies Honored With Belfast Ambassador Award at Belfast Business Top 50 Event 2Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia 2Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia 3
(Date:6/30/2015)... New York (PRWEB) , ... June 30, 2015 ... ... ( http://www.xareltolawsuit2015.com/ ) currently pending in a federal multidistrict litigation now underway in ... Court convenes its next monthly Status Conference. According to the Court’s calendar, that ...
(Date:6/30/2015)... NJ (PRWEB) , ... June 30, 2015 , ... Dr. ... primary care sports medicine physician. He specializes in the diagnosis and treatment of non-surgical ... and for the people who participate in recreational athletics and use exercise to stay ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates today ... Healthcare Research & Analytics , a consultative healthcare market research practice that is ... businesses. HRA offers quantitative and qualitative, custom and multi-client primary market research services ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... partnering to improve access to cancer prevention, screening and care for the people ... announced an affiliation that will see Roswell Park faculty providing clinical consultations to ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... New Energy ... York July 7th and 11th 2015. Timber frame post and beam raisings offer a ... , “Raising a timber frame is an important and exciting event – ...
Breaking Medicine News(10 mins):Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 2Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 3Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 4
... French . , MONTREAL, December 14, 2010 The first ... to recognize the sound of their parents, voice and the parents ... and newborns admitted to the intensive care unit can be very ... Jan Lariviere, a nurse in the neonatal clinic and the Neonatal ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Most ... United States is funded by states, not the federal government, ... variation in the extent to which states prioritized human embryonic ... in states could likely have been funded under federal government ...
... a woman in New Hampshire have received the first kidney ... Organ Procurement and Transplantation Network (OPTN) that uses a Carnegie ... donors. Both recipients Ken Crowder of St. Louis and ... were willing to donate a kidney but who were medically ...
... (HealthDay News) -- A federal judge ruled Monday that the ... government has no authority to require citizens to buy health ... new legislation, signed into law in March by President Barack ... supporters and opponents of the legislation anticipate the validity of ...
... that alter the activity of genes direct changes to ... control when genes are switched on and off, called epigenetic ... an opening for the cancerous growth of cells. Researchers ... at work on a genome-wide scale in cases of ovarian ...
... HealthDay Reporter , MONDAY, Dec. 13 (HealthDay News) ... may be child,s play, researchers report. A new ... cereals if they,re given a selection of choices at breakfast, ... fruit instead. The 5-to-12-year-olds in the study still ate ...
Cached Medicine News:Health News:Once upon a time in the Intensive Care Unit ... 2Health News:States Now Fund Most Embryonic Stem Cell Research in U.S. 2Health News:2 people receive kidney transplants in pilot program using CMU software 2Health News:2 people receive kidney transplants in pilot program using CMU software 3Health News:Federal Judge Strikes Down Health Reform Law 2Health News:Federal Judge Strikes Down Health Reform Law 3Health News:Ovarian cancer advances when genes are silenced 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 3
Reagent Basin, 60mL, 5/Box...
For use with 8 channel pipets....
96 channel Parallel dispenser using Positive Air Displacement Technology...
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
Medicine Products: